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Synthetic glucocorticoids (sGCs) such as dexamethasone (DEX), while used to mitigate inflammation and disease
progression in premature infants with severe bronchopulmonary dysplasia (BPD), are also associated with sig
nificant adverse neurologic effects such as reductions in myelination and abnormalities in neuroanatomical
development. Ciclesonide (CIC) is a sGC prodrug approved for asthma treatment that exhibits limited systemic
side effects. Carboxylesterases enriched in the lower airways convert CIC to the glucocorticoid receptor (GR)
agonist des-CIC. We therefore examined whether CIC would likewise activate GR in neonatal lung but have
limited adverse extra-pulmonary effects, particularly in the developing brain. Neonatal rats were administered
subcutaneous injections of CIC, DEX or vehicle from postnatal days 1–5 (PND1-PND5). Systemic effects linked to
DEX exposure, including reduced body and brain weight, were not observed in CIC treated neonates. Further
more, CIC did not trigger the long-lasting reduction in myelin basic protein expression in the cerebral cortex nor
cerebellar size caused by neonatal DEX exposure. Conversely, DEX and CIC were both effective at inducing the
expression of select GR target genes in neonatal lung, including those implicated in lung-protective and antiinflammatory effects. Thus, CIC is a promising, novel candidate drug to treat or prevent BPD in neonates
given its activation of GR in neonatal lung and limited adverse neurodevelopmental effects. Furthermore, since
sGCs such as DEX administered to pregnant women in pre-term labor can adversely affect fetal brain develop
ment, the neurological-sparing properties of CIC, make it an attractive alternative for DEX to treat pregnant
women severely ill with respiratory illness, such as with asthma exacerbations or COVID-19 infections.

1. Introduction
Preterm infants, especially those born earlier than 28 weeks of
gestation, have a significant risk of developing bronchopulmonary
dysplasia (BPD) (Davidson and Berkelhamer, 2017), with an incidence
estimated to be ~45% (Rutkowska et al., 2019). It remains the most

expensive complication of prematurity in terms of average cost per
hospitalization and is a primary factor contributing to length of hospital
stay. In addition, there are increased costs and potential morbidities
associated with therapies related to the treatment of BPD, such as nitric
oxide, oxygen supplementation, potential for tracheostomy, and other
associated care (Kalikkot Thekkeveedu et al., 2017). Current clinical
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strategies to reduce the incidence and severity of BPD include gentle
ventilation, avoiding extremes of oxygenation, and pharmacotherapy
including diuretics, and bronchodilators, as well as inhaled or intra
tracheal budesonide or systemic dexamethasone (DEX), a long-acting
synthetic glucocorticoid (sGC). While helpful in many cases for
reducing inflammation and disease progression in BPD, systemic sGC
administration unfortunately can be associated with adverse side effects,
and it has been implicated in detrimental and persistent effects on infant
neurodevelopment, including alterations in brain architecture and
behavior (Cheong et al., 2014; Kraft et al., 2019).
Recent outcome studies after postnatal DEX administration demon
strate increased risk for cerebral palsy, abnormal neurologic examina
tions, and higher Major Depression Inventory scores depending upon
both the dose and the age of the infant at the time of sGC initiation (Kraft
et al., 2019; LeFlore and Engle, 2011; Malaeb and Stonestreet, 2014).
Despite efforts to minimize adverse neurodevelopmental outcomes by
limiting use of sGC to older (7–14 days postnatal) and more severely
affected infants, neonates in these groups continue to remain at risk for
other significant systemic side effects such as hyperglycemia, hyper
tension, gastrointestinal bleeding, and infection (Malaeb and Stone
street, 2014). Hydrocortisone, a less potent and short acting GC often
used in place of DEX, also results in side effects such as adrenal insuf
ficiency (Ng et al., 2004) and increased risk of spontaneous intestinal
perforation (Peltoniemi et al., 2005). In summary, there remains a need
for a treatment that will have the desired anti-inflammatory and tissue
maturation effects on neonatal lungs, while limiting negative systemic
side effects, including those in the developing brain.
Ciclesonide (CIC) is a new generation inhaled sGC currently
approved for the treatment of asthma and allergic rhinitis. It is a prodrug
that is converted by carboxylesterases (CES) enriched in the lower
airway into the active compound des-ciclesonide (des-CIC) (Mutch et al.,
2007; Sato et al., 2007), which has a 100-fold higher binding affinity to
the GC receptor (GR) than the parent (inactive) compound (Daley-Yates,
2015). In addition, des-CIC has optimal pharmacokinetics, with 99% of
drug being protein-bound in the serum (bioavailability of <1%), and >
99% first-pass metabolism in the liver – which, combined with targeted
activation by airway CESs, makes it an ideal candidate for avoidance of
systemic, and in particular, neurologic effects (Daley-Yates, 2015; Nave
et al., 2004; Nonaka et al., 2007). The pharmacokinetic (PK) properties
of CIC and des-CIC evaluated in adult humans and rodents further
enhance its potential benefit to treat neonatal lung injury. Specifically,
fatty acid esterification of des-CIC increases its tissue residency time in
lung and is the basis for the current once daily dosing regimen of CIC
recommended in adults and children (Nave and McCracken, 2008).
Furthermore, des-CIC accumulation in rodent brain is highly limited and
can be an order of magnitude less than those in lung even after multiple
doses (Mars et al., 2013). Clinical studies, including with pediatric
subjects, have shown non-inferiority of CIC in terms of managing res
piratory symptoms compared to other standard sGCs used in asthma
management, and a safety profile comparable to current first-line ther
apies (Maglione et al., 2018; Postma et al., 2017). Additionally, CIC does
not appear to cause unwanted systemic adverse effects often observed
with other systemic or inhaled sGCs, such as adrenal suppression,
reduced long bone growth, or neurologic impairment. In fact, CIC has
been used successfully in children as young as 6 years old as an alter
native asthma therapy to current first-line agents to reverse adrenal
suppression while still controlling respiratory symptoms (Liddell et al.,
2017; Pedersen et al., 2006; Pedersen et al., 2010; Skoner, 2016).
Given the potential for serious systemic side effects following
neonatal sGC administration, alternative GR-targeting drugs for BPD
treatment need to be evaluated, particularly those drugs with potential
to limit adverse effects in the brain. Many of the persistent detrimental
effects of postnatal sGCs in humans have also been observed in rodent
models (Bhatt et al., 2013; de Kloet et al., 2014; Feng et al., 2009; Lee
et al., 2012), allowing us to evaluate CIC mechanism and targets in
comparison to DEX using a model organism. For example, because the

saccular stage of newborn rat lung development (i.e., E21-PND4)
matches the stage of human lung development typically attained in
premature infants (i.e., saccular stage between 24 and 38 gestational
weeks of age) (Schittny, 2017) they provide an ideal initial paradigm to
evaluate localization-specific CIC responses. Herein, we demonstrate
that DEX and CIC can regulate various GR targets in the newborn rodent
lung, including both ubiquitously responsive genes and those implicated
in lung protective effects. However, CIC does not suppress somatic
growth nor induce the neuroanatomical changes in the cerebral cortex
and cerebellum that are established consequences of DEX exposure in
neonates. Therefore, CIC, a drug that has been evaluated in clinical trials
for children as young as 2 years old (ClinicalTrials.gov Identifier:
NCT00261287 (Brand et al., 2011)) is an attractive candidate for future
evaluation as an alternative sGC to treat or prevent BPD.
2. Material and methods
2.1. Animal care
Animal experiments were performed in accordance with the NIH
Guide for the Care and Use of Animals and approved by the University of
Pittsburgh Animal Care and Use Committee as were images used in this
publication. In addition, the use of C57Bl/6 mice in this study was
approved by the Monash University Animal Research Ethics Committee.
2.2. sGC injections
Timed-pregnant Sprague Dawley rats (Charles River) were housed
individually in standard microisolator cages with food (Prolab Isopro
RMH 3000, LabDiet) and water ad libitum under a 12-h light cycle from
7a-7p and allowed to give birth. Within 24 h of birth (PND1), pups were
weighed individually and divided among three treatment groups,
vehicle (VEH), 0.5 mg/kg DEX, or 0.5 mg/kg CIC, a dose which has been
used in a similar study (Kim et al., 2013). Stock solutions (10− 2 M) of
DEX and CIC were prepared in 100% ethanol and stored at − 20 ◦ C. Prior
to injections, the stocks were diluted to a concentration of 50 mg/ml in
sterile saline. VEH consisted of 100% ethanol diluted in sterile saline
using identical dilution parameters to DEX. Compounds were adminis
tered subcutaneously (SC) at the nape of the neck via a 31G needle not to
exceed 10 μl/g once a day for up to 5 consecutive days on postnatal days
(PND1–5) . Pups were weighed daily prior to injection. DEX treated
neonates were given additional injections of sterile saline as needed if
showing signs of dehydration. Both male and female rats were included
in this study.
2.3. Tissue fixation, immunohistochemistry (IHC) and anatomical
evaluation
For analysis of neonatal C57Bl/6 mouse lung, PND1 and PND5 tissue
was collected and fixed in 4% paraformaldehyde, embedded in paraffin
blocks, and 5 μM sections cut and mounted on slides. Sections were
stained using a rabbit polyclonal antibody to detect CES1d (Invitrogen,
PA5–19740, 1:200 dilution) with visualization by diaminobenzidine
staining and counterstaining with eosin, as described previously (Bird
et al., 2014).
For anatomical and myelination evaluations, PND15 rat brains were
fixed in 10% neutral buffered formalin (Formal-Fixx, Shandon, Thermo
Scientific) overnight at 4 ◦ C then processed through increasing con
centrations of sucrose (10, 20, 30% in phosphate buffered saline (PBS)).
Photographs were taken of fixed PND15 brains with an iPhone XS
(Apple, Inc.) mounted (Universal Cell Phone Adapter Mount, Gosky
Optics) under magnification on a stereomicroscope at 7× (MZ6 modular
stereomicroscope, Leica Microsystems).
Fixed rat brain tissue was embedded in Tissue Tek (Scigen Scientific)
compound, frozen and consecutive sagittal sections (30 μm) were
collected of the cerebellum or coronally from the forebrain. Cerebellar
2
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sections were incubated in PBS with 0.05% Tween 20 followed with
fluorescent Nissl stain for 2 h in a solution containing 5% BSA, 5% goat
serum, 0.3% triton X100, 5% glycine in PBS (NeuroTrace 500/525,
Thermo Fisher Scientific, N21480, 1:5000). For myelin staining in the
cerebral cortex, consecutive 30 μM coronal forebrain sections were
collected from every 4th section, incubated with an anti-MBP antibody
(Invitrogen PA578397) overnight, and subsequently incubated with a
biotinylated secondary antibody, avidin/streptavidin amplification with
the Vector ABC kit (Thermo Fisher Sci, P132054) and subsequent visu
alization with diaminobenzidine staining and counterstained with eosin.
Images were visualized at 10× and 20× on an EVOS cell imaging system
(Fisher Scientific), photographed, imported and figures assembled in
Adobe Photoshop.

extraction method and cDNA prepared using the iScript cDNA kit (BioRad). qRT-PCR analysis was performed using a Bio-Rad SYBR Master
Mix and run on a CFX96 Real-Time System/C1000 Touch thermal cycler
using Bio-Rad CFX Manager 3.1 software. A table of primers utilized in
this study is included in the supplemental material (sTable 1). Fold
change was calculated using the 2-ΔΔCt method as described previously
(Livak and Schmittgen, 2001). ΔCt values for vehicle-treated animals
were averaged within litters for lung inflammation gene assessment, and
ΔΔCt values for DEX- and CIC-treated animals were calculated from the
average ΔCt values from their respective vehicle-treated littermates.
Fold change values were used to compare gene expression between
treatment groups.
2.6. Statistical analysis

2.4. Protein immunoassays

Data analysis was conducted with SAS software (IBM SPSS Statistics
25) or GraphPad statistical software (Prism, version 9). A one-way
ANOVA for comparison of multiple groups followed by the appro
priate post hoc test as indicated (e.g., Dunnett’s test, Tukey, Bonferroni).
If the Brown-Forsythe indicated significantly unequal variance between
groups, a nonparametric Kruskal-Wallis test was used (indicated by H
statistic), followed by a Dunnett’s post hoc test. For the growth curve,
GraphPad version 9 (Prism) was used for two-way ANOVA with
repeated measures followed by Bonferonni post hoc at the daily time
points. Results are presented as the mean ± SEM.

The Jess System (Protein Simple) was used for capillary-based pro
tein immunoassays of CES1d (Abcam, ab68190, 1:10,000) and β-actin
(Proteintech, HRP-60004, 1:100) in tissue collected from untreated rat
neonates including lung, cerebellum, and cortex. At PND1 and PND5
tissues were collected and protein lysates prepared in RIPA buffer pro
cessed according to Protein Simple using the supplied reagents after BCA
assay (Pierce) to determine total protein. Separation modules were
loaded into the Jess System, and proteins underwent separation by size
within capillaries prior to automated immunodetection. The secondary
HRP conjugated antibodies were from Protein Simple.
Similarly, total and phosphorylated glucocorticoid receptor (GR)
from PND1 and PND2 rat lung was examined in treated animals. At 4
and 24 h after SC injection with 0.5 mg/kg DEX, 0.5 mg/kg CIC or VEH
on PND1, lung tissue was collected, and instructions utilizing the sup
plied reagent kits. Antibodies used to detect total GR (Cell Signaling
Technology, 47,411, 1:50) or GR phosphorylated at serine 232
(orthologous to serine 211 in human) (Cell Signaling Technology, 4161,
1:100) and serine 246 (226 in human) (Cell Signaling Technology,
97,285, 1:100) were from Cell Signaling. The secondary HRP conjugated
antibodies against mouse or rabbit were from Protein Simple. Relative
protein expression was quantified with the Compass software (Protein
Simple) using the total protein normalization module for the Jess System
(Protein Simple).
MBP expression was assessed at PND15 following daily SC injections
from PND1-PND5 with 0.5 mg/kg DEX, 0.5 mg/kg CIC or VEH. Specif
ically, forebrain lysates were prepared from tissue isolated using a brain
block to obtain 3 mm coronal sections of the rat forebrain containing the
body of the corpus callosum anterior to the hippocampi. Tissue was
homogenized by sonication on ice in RIPA buffer containing 50 mM Tris
HCl pH 8.0, 1% Triton x-100, 0.5% Na-deoxycholate, 0.1% SDS with 1×
HALT Protease and Phosphatase inhibitor cocktail (Thermo Scientific).
10 μg of total protein as determined by BCA (Pierce) for each sample was
separated on a 10% TruPage premade gel with MOPS running buffer
(Sigma). Proteins were then transferred to a PVDL-FL membrane (Mil
lipore). The membrane was blocked in Odyssey Blocking Buffer (LiCor)
then incubated overnight with an antibody against MBP (Cell Signaling
Technology, 78,896, 1:2000) and glyceraldehyde 3-phosphate dehy
drogenase (GAPDH) (Santa Cruz Biotech, sc-32,233, 1:2500) followed
by incubation with secondary antibodies (goat anti-rabbit 800, Licor
92,603,221, 1:1000) and goat anti mouse 680 LiCor 926–32,220,
1:1000). Processed membranes were imaged on an Odyssey CLx infrared
scanner (LiCor Bioscience) and analyzed with the Image Studio Lite Ver
5.2 (LiCor Bioscience).

3. Results
3.1. Tissue specific Ces gene expression in neonatal lung across species
exceeds brain expression
To support the feasibility of CIC use in neonates, we evaluated
expression levels of CIC-activating enzymes, the Ces family genes (CES
in humans, Ces in mouse/rat (Holmes et al., 2010)) by interrogating
publicly available genome-wide data sets from multiple species. We
assessed expression levels in lung, liver, and brain tissue collected at late
embryonic through term neonatal ages to represent the developmental
spectrum of human infants at risk for BPD, encompassing gestational
ages of premature through term infants. Because CIC hydrolysis and
activation are not known to be limited to a specific Ces subgroup (Mutch
et al., 2007; Nave and McCracken, 2008) and additional Ces isoenzymes
have been identified in mice and rats compared to humans (Holmes
et al., 2010; Jones et al., 2013; Lian et al., 2018), we broadly considered
all identified Ces isoforms reported.
Analysis of scRNA-Seq datasets from PND1 human lung revealed
expression of two CES genes, (i.e., CES1 and CES2) in multiple cell types
(sFig. 1) (Du et al., 2015; Du et al., 2017; Guo et al., 2019). Although
only a few studies have quantified expression of CES genes in human
fetal and neonatal brain and a complete regional inventory is unavai
lable, CES genes appear to have limited expression in this organ (Keil
et al., 2018; Miller et al., 2014) (http://www.brainspan.org/rnaseq/se
arch/index.html http://hbatlas.org/). These observations provide
initial support for organ-specific activation of CIC based on CES enzyme
expression in human neonates.
Given that mice are frequently used as model organisms for perinatal
pathology, we also investigated published single cell scRNA-seq data in
late fetal and neonatal mouse lung (Du et al., 2015; Du et al., 2017; Guo
et al., 2019) to provide more comprehensive assessments of Ces gene
expression, particularly in specific lung cell types. Ces1d, the ortholog of
human CES1 (Lian et al., 2018) is the most highly expressed isoform in
neonatal mouse lung (sFig. 2A,B) with expression in multiple distinct
cell types in the lung (sFig. 2A,B) with Ces2g the only other isoform with
expression above background (sFig. 2C,D). Cell type-specific expression
of CES1d protein in PND1 and PND5 mouse lung was confirmed by IHC
analysis (sFig. 3). To broaden the evaluation of Ces isoform gene
expression to other tissues, we interrogated genome-wide bulk RNA-seq

2.5. qRT-PCR
RNA was isolated from frozen rat tissues collected at multiple post
natal time points (untreated for Ces expression analysis at PND1, PND2,
PND15; and 4 and/or 24 h post treatment administered on PND1 for
expression of genes driven by GR activation) using a Trizol (Invitrogen)
3
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data from mice (Darbellay and Necsulea, 2020) (GEO:GSE108348).
These analyses revealed relatively high levels of mRNA expression in
late embryonic and/or newborn liver of a number of the 18 identified
Ces genes (i.e., Ces1c, Ces1d, Ces2a, Ces2e, Ces2g, Ces3a). Contrarily, in
the late embryonic or neonatal brain, Ces mRNA expression was limited
or undetectable (sTable 2).
We expanded our investigation to rats, because the saccular stage of
newborn rat lung development (i.e., E21-PND4) matches the stage of
human lung development typically attained in premature infants (i.e.,
saccular stage between 24 and 38 gestational weeks of age) (Schittny,
2017). Therefore, the lung developmental stage in newborn rats closely
models the premature human lung, an ideal initial paradigm to evaluate
localization-specific CIC responses. Consistent with results obtained in
transcriptome studies of neonatal mouse tissue, genome-wide micro
array analysis of rat lung from various ages (Weng et al., 2006) and RNASeq datasets from multiple rat neonatal organs (Darbellay and Necsulea,
2020) revealed only a few isoforms with mRNA expression in neonatal
lung and no consistent mRNA expression of any isoform in neonatal
brain.
In validation experiments using qRT-PCR, Ces1d and Ces1e were the
only isoforms examined with mRNA expression above background in
neonatal rat lung and showed differential regulation during the neonatal
period. qRT-PCR analysis did not detect Ces2g mRNA above background
levels in neonatal rat lung tissue (i.e., PND1, PND2, PND15) (not
shown), which contrasts with scRNA-Seq data from mouse neonatal lung
(sFig. 2C,D). Specifically, Ces1d (Fig. 1A, F(2,8) = 7.363, p = 0.015, post
hoc *p < 0.05, Bonferroni, n = 3–4 per group) mRNA expression was

significantly higher at later ages (i.e., PND15 versus PND1 and PND2).
In contrast, Ces1e mRNA expression peaked at PND2 and was signifi
cantly higher than at PND1 and PND15 (Fig. 1A, F(2,8) = 9.446, p =
0.008, post hoc *p < 0.05, Bonferroni, n = 3–4 per group). CES1d
protein, the highest Ces isoform expressed in rodent neonatal lung
(sFig. 2A,B), was present in PND1 and PND5 rat lung as revealed by
Western blot analysis but not detected in neonatal brain regions,
including the cerebellum and cortex (Fig. 1B). In summary, the wealth of
publicly available genome-wide data sets, along with our internal vali
dations, confirms the expression of enzymes primarily responsible for
activating CIC in neonatal lung with limited brain expression in humans
and rodents.
3.2. DEX but not CIC hinders neonatal growth and reduces brain size
A daily dose of 0.5 mg/kg of DEX has previously been shown to
generate myelination defects in neonatal rats (Kim et al., 2013). While
allometric scaling parameters of therapeutic drug doses to convert be
tween neonatal rats and humans that take into account the unique
metabolic parameters of these age groups have not been fully delin
eated, the Human Equivalent Dose (HED) can be approximated using the
FDA-recommended exponent of 0.67 to scale “no-observed-adverse-ef
fect-levels” between species based on surface area and the equation
HED = animal dose in mg/kg x (animal weight in kg/human weight in
kg)0.33 (Sharma and McNeill, 2009). Assuming an average neonatal rat
weight of 10 g and human infant weight of 3.5 kg, the HED of 0.5 mg/
kg/d would be approximately 0.07 mg/kg/day. This dose is below the

Fig. 1. CES expression in rat tissue. qRT-PCR analysis of (A) Ces1d and Ces1e (A) mRNA expression in lung tissue from neonatal rats collected at PND1, PND2 and
PND15. Fold change was calculated compared to expression of ß-actin mRNA levels on PND1 and compared using a one-way ANOVA followed by Bonferroni post hoc
analysis (*p < 0.05, **p < 0.01, n = 3–4 per group). (B) Protein expression of CES1d by Simple Western (Protein Simple). Representative immunoblot analysis is
shown for CES1d and β-ACTIN in PND1 and PND5 of lung, cerebellum, and cortex. CES1d was highly expressed in lung tissue at all ages with no detectable protein in
brain tissue.
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AAP recommended maximum “low” DEX dose for BPD (i.e., 0.2 mg/kg/
day) (Watterberg et al., 2010). However, given that biological effects in
rats are observed at 0.5 mg/kg and given our goal to seek a minimally
effective dose, we evaluated biological effects of this dose for both DEX
and CIC. Our studies assume biological equivalence of identical doses of
DEX and CIC taking into account the 10-fold higher affinity of des-CIC
for GR than DEX (Sato et al., 2007) and a minimum 10% conversion
of CIC to des-CIC.
During the course of our treatment paradigm, we observed a distinct
phenotype in DEX-treated neonates compared to either vehicle- or CICtreated animals. Specifically, neonatal rat pups treated with DEX
showed significant growth restriction (weight and length), decreased
development of fur, as well as thinner and translucent skin as compared
to the other groups (Fig. 2A). In addition, DEX-treated pups frequently
required supplementation with normal saline during the treatment
period to avoid death from dehydration/malnutrition; this complication
was not due to inability to nurse, as milk was visualized in the pups’
stomachs regularly throughout the same period, and mothers did not
demonstrate neglect of these pups.
Weight gain in treated pups was assessed daily from PND1-PND15.
As shown in Fig. 2B, weight gain in CIC and vehicle treated neonates
did not significantly differ throughout the entire period of our study (i.
e., PND1-PND15). However, DEX treated neonates exhibited slower
weight gain during the 5-day treatment period, a differential which
persisted even after completion of treatment up to PND15. From PND10
– PND15, all groups gained approximately 2 g daily regardless of
treatment. From PND4 to PND15, DEX treated animals were signifi
cantly smaller than both VEH and CIC treated animals and were

additionally significantly smaller than CIC treated animals on PND3
(Fig. 2B).
Gross examination of brains collected from PND15 demonstrated an
overall smaller size and less developed cortex and cerebellum (repre
sentative fixed brains shown in Fig. 2C). Total brain weight in DEX
treated animals was significantly decreased at PND6 and PND15
(Figs. 2D,E). There was no significant difference between vehicle- and
CIC-treated animals in terms of total brain weight, but by PND6, brain
weight was decreased by 23% in DEX-treated animals compared to VEH
(Fig. 2D); and by 12% at PND15 (Fig. 2E) Therefore, CIC does not
generate the systemic adverse effects in somatic and brain growth as
triggered by the potent GR agonist, DEX.
3.3. Transient neonatal DEX but not CIC reduces MBP accumulation in
the cortex
Use of sGCs in human neonates has been linked to a high risk for
white matter injury, a serious adverse effect that limits widespread use,
despite their potential beneficial anti-inflammatory actions for BPD
treatment (Watterberg et al., 2010). In neonatal rodents, myelination
initiates after birth in a caudal to rostral manner and continues into
adulthood (Davidson and Berkelhamer, 2017; Rutkowska et al., 2019).
The young postnatal rodent is consequently sensitive to white matter
loss following transient exposure to sGCs (Kim et al., 2013). Therefore,
CIC and DEX effects on white matter were evaluated in the forebrain at
PND15, when significant myelinated fibers are present in the caudate
putamen, globus pallidus, internal capsule, and corpus callosum. IHC
analysis demonstrated a notable reduction in MBP expression after DEX

Fig. 2. Differential effects of DEX and CIC on overall growth and brain size in rat neonates. Rats were treated with daily injections with VEH, 0.5 mg/kg DEX, or 0.5
mg/kg CIC from PND1 - PND5 and allowed to nurse until sacrifice at PND15. Representative images of (A) PND15 pups and (C) whole fixed brains following
treatment with VEH (left), DEX (middle) or CIC (right). (B) Growth curves reveal transient neonatal growth restriction following DEX but not CIC treatment. From
PND3 to PND15, body weights of CIC and DEX treated animals were significantly different (** p < 0.05 two-way repeated measures ANOVA, F(28,252), F = 10.75 p <
0.0001, Bonferonni post hoc, n = 7 per treatment). From PND4 to PND15, the body weights of VEH and DEX treated animals were significantly different (*p < 0.02,
two-way repeated measures ANOVA, F(28,252), F = 10.75, p < 0.0001, Bonferonni post hoc, n = 7 per treatment). Decreased total brain weight following DEX but not
CIC treatment of neonates. DEX treated animals had significantly decreased brain weights than VEH treated at PND6 (panel D, *p = 0.005, F(2,27) = 23.090, p <
0.001, Dunnett’s post hoc, n = 3–4 per group) and PND15 (Panel E, *p < 0.001, F(2,27) = 26.062, p < 0.001,Dunnett’s post hoc, n = 10 per group). CIC had no
significant effect on brain weight.
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exposure in the corpus callosum (Fig. 3B) and the striatum (Fig. 3E), a
phenotype which was not triggered after CIC exposure (Figs. 3C, F).
Conversely, the anterior commissure appeared less susceptible to DEX
driven effects (Figs. 3G-I). The reduction in IHC immunoreactivity was
quantified with western blot analysis of MBP in cortex/corpus callosum
tissue. Specifically, DEX treatment resulted in a decrease of MBP
expression by 62% to that in the VEH animals. CIC did not significantly
decrease MBP expression in cortex/corpus callosum (Figs. 3J, K). In
summary, IHC and western blot analysis of MBP corroborate the detri
mental effects of the GR agonist, DEX, on white matter development
during the rodent neonatal period (Kim et al., 2013) but reveal no sig
nificant effect in neonates exposed to the GR prodrug CIC.

3.5. CIC and DEX increase site specific GR phosphorylation in neonatal
lung
In addition to minimizing systemic and neurologic adverse effects,
CIC viability as an alternative to DEX requires activation of GR in
neonatal lung. In order to provide a broad assessment of GR activation in
neonatal lung, agonist-regulated site-specific phosphorylation of GR was
measured. GR can undergo transient phosphorylation at multiple sites
(Galliher-Beckley and Cidlowski, 2009), and conserved serine residues
at position 232 in rat (S232, S211 in human) and 246 (S246, S226 in
human) exhibit increased phosphorylation following agonist binding to
the receptor. Phosphorylation status at each of these sites can impact
gene-specific transcriptional responses (Chen et al., 2008; GalliherBeckley and Cidlowski, 2009; Peffer et al., 2014), though the kinetics
and magnitude of site-specific GR phosphorylation varies in different
cell types (Lynch et al., 2010).
As shown in Fig. 5A and B, a 4-h DEX or CIC treatment at PND1
triggered an increase in GR phosphorylation at S232 in lung while DEX
also induced S246 phosphorylation, demonstrating that CIC has the
capacity to bind to and activate GR in neonatal lung. These hormoneinduced phosphorylation events were transient and not observed at 24
post-treatment (Fig. 5C). Increased rates of phosphorylated GR were not
due to increases in total steady state levels of intact GR (i.e., 95 kDa), for
which no significant differences were seen at either 4- or 24-h posttreatment (Figs. 5B,C). However, 4 h after CIC treatment, a significant
reduction in the 55 kDa GR isoform (presumedly representing the pre
viously characterized translational “D” isoform (Lu and Cidlowski,
2005)) was observed (Fig. 5B), but were not significantly different by 24
h of treatment (Fig. 5C). Thus, CIC has the capacity to activate agonistspecific changes in GR phosphorylation in neonatal lung.

3.4. Transient neonatal DEX but not CIC reduces cerebellar size
Previous studies have established that exposure to DEX in the
neonatal period can lead to neurodevelopmental consequences, specif
ically with targeted effects in the cerebellum that present as an overall
decrease in cerebellar size (Heine and Rowitch, 2009; Noguchi, 2014).
After our treatment paradigm of exposures from PND1–5, we assessed
cerebellar anatomy on PND15 and confirmed that our model replicated
the established DEX-mediated diminutive phenotype (Fig. 4B) as
compared to VEH (Fig. 4A). We also evaluated the PND15 brain after
CIC treatment, which did not appear to result in decreased size (Fig. 4C).
Examination of midline sections by fluorescent Nissl staining at the level
of the cerebellar vermis highlights the overall decrease in size noted
after exposure to DEX (Fig. 4E) but not CIC (Fig. 4F) compared to VEH
(Fig. 4D). In summary, the adverse effects of neonatal DEX exposure on
both the forebrain and cerebellum are not observed with CIC.

Fig. 3. Differential effects of DEX and CIC on myelination in the forebrain of neonatal rats. Brains were collected on PND15 from rats that were given daily injections
of DEX, CIC or VEH from PND1-PND5. IHC of MBP in PND15 brains from animals treated with VEH (A,D,G), DEX (B, E, H) and CIC (C, F, I). Representative
photomicrograph of the corpus callosum (panels A-C), striatum (panels D–F) and anterior commissure (panels G-I) (are shown (Scale bar, 100 μm). (J) Repre
sentative Western blot of cortex/corpus callosum tissue lysate of PND15. (K) Relative levels of MBP protein levels to loading control GAPDH. DEX significantly
decreased MBP as compared to VEH and CIC (*p < 0.05, F(2,12) = 9.403, p = 0.003, Tukey post hoc, n = 5 per group). CIC did not significantly affect MBP expression
compared to VEH.
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Fig. 4. Differential effects of DEX and CIC on cerebellar size and foliation in neonatal rats. Neonatal rats were treated with daily injections of VEH (A,D),0.5 mg/kg
DEX (B,E), or 0.5 mg/kg CIC (C,F) daily from PND1 - PND5 and brain tissue was collected on PND15. Representative gross images of cerebella from VEH (A), DEX (B),
and CIC (C) treated rats showing the smaller size of the cerebellum in the DEX-treated animal compared to VEH and CIC. Representative photomicrographs of
cerebellum from VEH (D), DEX (E), and CIC (F) treated rats along midline through the vermis stained with fluorescent Nissl. Three brains were examined
per treatment.

3.6. CIC and DEX mobilize lung-protective transcriptional responses in the
neonate

Given the ability of CIC to induce transcription of broadly expressed
GR target genes in neonatal lung, we then examined effects of CIC
treatment on the expression of GR-regulated genes whose response is
likely to contribute to the therapeutic effects of sGC in BPD. These genes
were assessed 24 h following treatment to evaluate the viability of CIC to
exert enduring effects on putative lung-protective genes. As shown in
Fig. 7, basal mRNA expression of a number of pro-inflammatory genes in
neonatal lungs was repressed to the same extent 24 h following DEX or
CIC treatment of PND1 pups. The GR target genes repressed by DEX and
CIC included Icam1, Il-8 and Tnfα (Fig. 7A-C). DEX and CIC treatment
also induced genes that promote angiogenesis (i.e., Vegf, Dll4, Angpt2)
(Fig. 7D-F) or alveolar type II and type I epithelial cell function (i.e., Spc,
Aqp5) (Fig. 7G,H) in neonatal lung. Specific differences in the response
of these genes were noted for Angpt2 (Fig. 7F), which was significantly
induced by CIC but not DEX, whereas Spc achieved a statistically sig
nificant induction following DEX but not CIC treatment (Fig. 7G).
In summary, qRT-PCR results show that CIC has the capability to
induce changes in expression in both widely expressed and functionally
relevant GR-regulated genes, though individual gene responses
compared to DEX are not identical. Specifically, while CIC transcription
induction of the ubiquitously responsive GR targets in lungs noted at 4 h
did not seem to persist as long as after DEX exposure, significant changes
in transcription of lung genes associated with BPD pathology were still
observed 24 h post-exposure. Additionally, CIC treatment does not
appear to lead to significant mobilization of GR responses in the brain,
reinforcing that the unique pharmacokinetics and pharmacodynamics of
CIC may promote organ-specific GC action that spares the developing
brain.

To evaluate if CIC-induced GR activation led to a similar transcrip
tional induction or suppression of GR-regulated genes, qRT-PCR analysis
was performed after VEH, DEX, or CIC treatment in PND1 rats. In order
to compare target organ effects in the lung to unintended off-site effects
in the brain, we first evaluated a variety of GR target genes that are
broadly expressed in multiple organs (e.g., Per1, Gilz, Fkbp5), and which
have been previously characterized as widely responsive to sGC expo
sure by our lab and others (Al-Safadi et al., 2015; Binder, 2009; Peffer
et al., 2014; Srinivasan and Lahiri, 2017). Per1, or PERIOD1, is a GCresponsive circadian clock protein that is increases after exogenous or
endogenous hormone exposure (Al-Safadi et al., 2015). Gilz, or gluco
corticoid induced leucine zipper, is hypothesized to have antiinflammatory and/or neurogenic functions, and also is induced by GC
exposure (Srinivasan and Lahiri, 2017). Fkbp5 (FK506 binding protein 5)
is a gene induced by GC exposure and functions in a negative feedback
mechanism to desensitize the GR response (Binder, 2009).
At 4 h post-treatment, both DEX- and CIC- treatment induced the
expression of Per1 and Gilz mRNA in lung compared to VEH (Fig. 6A,B),
though Fkbp5 was only significantly induced by DEX at 4 h despite an
increasing trend after CIC exposure (Fig. 6C). At 24 h, Gilz and Fkbp5
continued to be significantly induced by DEX, but not CIC (Fig. 6A-C).
These results demonstrate that CIC has the capability to mobilize tran
scription of GR-regulated genes, although the duration of gene specific
responses may differ between CIC and DEX. Furthermore, although DEX
significantly induced Gilz at 24 h and Fkbp5 at 4 h in the cerebellum,
none of these genes were significantly induced by CIC in the cerebellum
after 4 or 24 h (Fig. 6D-F).
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Fig. 5. Impact of DEX and CIC on GR protein expression and phosphorylation in neonatal rat lung. Rats were treated with VEH, 0.5 mg/kg DEX, or 0.5 mg/kg CIC on
PND1 and lung tissue lysates prepared following 4 or 24 h. (A) Representative Simple Western of PND1 lung tissue following 4-h treatment to detect total full length
95 kDa GR, a 55 kDa GR isoform, and GR phosphorylated at Ser 232 (pSer232) or Ser246 (pSer246). (B) Amount of full-length (GR95), 55 kDa (GR55), pSer232 or
pSer246 isoforms of GR normalized to total protein with Jess System software in lung following 4-h treatment initiated at PND1. Neither DEX nor CIC affected full
length GR. CIC significantly decreased GR55 levels (*p < 0.05, F(2,18) = 3.567, p = 0.05, Dunnett’s post hoc, n = 7 per group) while there was a trend for GR55 levels
to be decreased following DEX treatment. Conversely DEX increased pS232 (* p < 0.05, F(2,18) = 15.79, p = 0.0001, Dunnett’s post hoc, n = 7 per group) and pS246
(* p < 0.05, F(2,18) = 6.836, p = 0.0062, Dunnett’s post hoc, n = 7 per group), while CIC significantly increased pS232 but not pS246. (C) None of the changes in
GR55 or phospho-isoforms were observed 24 h following DEX or CIC treatment.

4. Discussion

plasticity in the hippocampus and memory deficits (Kalikkot Thekke
veedu et al., 2017). Our findings in neonatal rats after DEX exposure
recapitulate the documented reductions in MBP observed in the corpus
callosum, caudate, putamen, and globus pallidum (Kim et al., 2013).
Similar alterations in neonatal myelination were not observed after
exposure to CIC.
Furthermore, in neonatal rats, DEX administration caused a char
acteristic and robust phenotype of skin and fur abnormalities, somatic
growth restriction, and decreased brain weight that was notably absent
in the CIC-treated pups. DEX suppresses insulin growth factor 2 (IGF-2)
levels to values similar to those found in Igf-2 knockout mice (Pew et al.,
2016), which provides a plausible mechanism for reduced neonatal
growth we observed in DEX but not CIC treated rats. Unlike in older
animals, the neonatal period in mammals including rat (Levine, 2002) is
designated as a stress hyporesponsive period, as levels of circulating GCs

Significant evidence has accumulated indicating that perinatal sGC
exposure leads to adverse consequences on neonatal brain development.
Perinatal administration of DEX to infants at risk for BPD has been
associated with abnormal brain development in both rodents and
humans (Heine and Rowitch, 2009; Kim et al., 2013; Noguchi, 2014).
Studies in rodents have shown that DEX leads to a reduction in myeli
nation by targeting oligodendrocyte progenitor cells (Cheong et al.,
2014), which may provide some explanation as to why in the neonatal
period, the developing brain is particularly vulnerable to white matter
injury. Consistent with these findings, in both human and animal
models, neonatal DEX exposure is associated with exacerbation of white
matter injury with increased risk for cerebral palsy and motor impair
ments (Kalikkot Thekkeveedu et al., 2017), as well as aberrant synaptic
8
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Fig. 6. Activation of select GR target genes in neonatal lung and brain following DEX or CIC treatment. PND1 rat pups were treated with 0.5 mg/kg CIC, 0.5 mg/kg
DEX, or VEH, and tissues collected at 4 or 24 h post injections. Fold change of Per1 (A,D), Gilz (B,E) and Fkbp5 (C,F) mRNA were measured (normalized to ß-actin
mRNA levels in VEH-treated rats) by qRT-PCR. Data were analyzed using a one-way ANOVA followed by a post hoc Bonferroni’s multiple comparisons test unless
groups were determined to have significantly unequal variance, when a nonparametric Kruskal-Wallis test (H statistic) was used followed by a Dunnett’s post hoc
test. Post hoc test significance is annotated as follows: *p < 0.05, **p < 0.01, ***p < 0.001. In lung, 4 h after treatment on PND1, significant induction of Per1 (F(2,9)
= 24.92, p = 0.0002) and Gilz (F(2,9) = 19.56, p = 0.0005) mRNA was observed with both DEX and CIC (A,B). In contrast, Fkbp5 was only induced by DEX at 4 (H(2) =
9.846, exact p = 0.0002) (C) and 24 h (H(2) = 13.07, approximate p = 0.0015). At 24 h in lung, Gilz continued to be significantly induced by DEX (F(2,9) = 16.73, p =
0.0009) (B). None of these genes were induced by CIC in the cerebellum after 4 or 24 h (D–F). DEX significantly induced Gilz at 24 h (F(2,9) = 14.24, p = 0.0016) and
Fkbp5 at 4 h (F(2,9) = 7.047, p = 0.0144) in the cerebellum (E,F) (n = 4 for all groups except lung Fkbp5 expression at 24 h for which n = 7–8, and cerebellar
expression of Gilz at 24 h n = 4–5).

are relatively low and they do not consistently respond to circadian cues
or pituitary-derived adrenocorticotropic hormone. Negative feedback of
the hypothalamic/pituitary/adrenal (HPA) axis by natural or synthetic
GCs is also not developed in the neonate (Levine, 2002). Therefore, is it
unlikely that endogenous hormone dysregulation from HPA feedback is
driving the well-established detrimental systemic and neurologic effects
of DEX administration.
The SC delivery of CIC employed in our studies, while shown to allow
for systemic distribution of des-CIC (Mars et al., 2013) was used for
practical reasons given the technical difficulties in administering drugs
intravenously (IV) or by inhalation (INH) in a neonatal rat pup. How
ever, nebulization is one option for administering CIC to patients with
BPD where local delivery could further enhance its therapeutic targeting
to lung and limit adverse sGC side effects that are particularly con
cerning for the neonate.
Despite utilizing this systemic administration route in our model, we
still did not see significant adverse neurologic effects in CIC-treated
neonates. A major contributor to this pattern of effects is likely reflec
tive of the site-specific generation of des-CIC in the lung, and thus pro
vides support that CIC is unlikely to be ectopically activated in the brain.
The highly protein-bound des-CIC (Nave et al., 2004; Nonaka et al.,
2007) may also have a limited ability to cross the blood-brain barrier
(BBB) in sufficient quantity prior to metabolic breakdown, although we
cannot exclude the possibility that CIC or systemically generated desCIC could cross the immature neonatal BBB of neonates or induce in
direct effects on neonatal brain function. More extensive CIC dosing
regimens and comprehensive phenotypic, neuroanatomical and tran
scriptome analysis in brain and lung could identify an optimal dosing

strategy for treating lung injury in neonates but limit adverse neuro
developmental effects.
When considering the potential for CIC, as a GR prodrug, to treat
neonatal human lung disease characterizing its ability to activate GR in
newborn lung is crucial for establishing viability of a novel safe treat
ment approach. GR activation can in turn advance maturation and
reduce inflammation, improving respiratory outcomes. Our studies in
neonatal rats suggest that CIC may have the potential to fulfill these
requirements, as CIC was capable of rapidly activating many GCresponsive genes in neonatal lung to a similar degree as DEX. In addi
tion, CIC can exert a long-lasting effect to reduce the baseline expression
of cytokine gene products that contribute to inflammatory lung injury as
well as increase the expression of genes that promote angiogenesis and
epithelial cell function. The ability of CIC to likewise trigger the anal
ogous site-specific phosphorylation of the GR suggests that phospho-GR
specific genome-wide transcriptional responses in lung may demon
strate some overlap between DEX and CIC treatments. However, subtle
differences in site-specific GR phosphorylation and translational isoform
regulation suggest that there may be some GR targets that exhibit dif
ferential responses to DEX versus CIC in neonatal lung that impact
downstream effects on respiratory outcome measures (Chen et al., 2008;
Galliher-Beckley and Cidlowski, 2009; Oakley et al., 2018; Peffer et al.,
2014). Furthermore, Ces gene expression has the potential to vary in
response to physiologic state. For example, Ces isoform expression was
altered in macrophages of high fat diet-fed mice exposed to lipopoly
saccharide (Jones et al., 2013), suggesting that an inflammatory disease
state could in turn affect Ces substrate metabolism. While a compre
hensive assessment of the individual relative abilities of CES enzymes to
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Fig. 7. CIC and DEX mobilize lung-protective transcriptional responses in the neonate. 24 h after treatment of PND1 rat pups with 0.5 mg/kg DEX, CIC, or VEH, lung
tissue was collected and subjected to qRT-PCR analysis of genes associated with protective and anti-inflammatory responses in the lung. All data were analyzed with a
one-way ANOVA followed by a Dunnett’s post-hoc test with *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 8/treatment group for all analyses. Both DEX
and CIC significantly repressed expression compared to VEH of Icam1 (A), Cxcl1 (B), and Tnfα (C). DEX and CIC treatment both induced pro-angiogenic Vegf (D) and
Dll4 (E), although Angpt2 was only significantly induced by CIC (F). Neonatal lung markers of alveolar type II and type I epithelial cell populations were induced by
DEX (G,H) although CIC induced Aqp5 (H) but not Spc (G).

hydrolyze CIC has not yet been performed, substrate specificity has been
documented with various CES enzymes (Wang et al., 2018). Thus, the
therapeutic potential of CIC as a sGC of choice in pediatric patients will
need to take into account potential pathologic effects on CES enzyme
expression and/or activity.
Given our initial promising data, future studies will move to evaluate
CIC within the context of relevant injury and/or prematurity models of
BPD in rodents and further characterize its effectiveness as a potential
therapeutic (Lesage et al., 2018). As pathologic inflammation and lung
remodeling processes are activated in BPD, a comprehensive charac
terization of CIC-mediated GR activation effects in neonatal lung injury
models will provide critical contextual effectiveness data and promote
timely translation into clinical studies. Developing a better under
standing of the scope of action and PK of CIC may also allow for
extrapolation of its use into additional scenarios where established sGC
treatments carry associated neurodevelopmental risks (Damsted et al.,
2011; Davis et al., 2013; Ilg et al., 2019; McGowan and Matthews,
2018).
In summary, our results provide the impetus to continue to evaluate
CES -metabolized GR prodrugs as a novel pharmacotherapy to mitigate
lung disease in human neonates, where use of currently available sGCs,
is limited due to the potential for severe adverse neurological and sys
temic side effects. The potential therapeutic use of CIC may not be
limited to asthma and BPD. For example, CIC has both antiinflammatory and anti-viral properties against the SARS CoV-2 virus
(Jeon et al., 2020; Matsuyama et al., 2020; Mori et al., 2021). Since sGCs
such as DEX administered to pregnant women in pre-term labor can

adversely affect fetal brain development, the neurological-sparing
properties of CIC, make it an attractive alternative for DEX to treat
pregnant women severely ill with respiratory illness, such as with
asthma exacerbations or COVID-19 infections (Delahoy et al., 2020;
Ellington et al., 2020).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.nbd.2021.105422.
Support
This work was funded by the National Institutes of Health grants R01
HD087288 to DBD and APM, R21 HD097694 to DBD, R01 HL128374 to
VS, K12 HD052892 career development award to ALF. EMB was sup
ported by a Magee-Women’s Research Institute Clinical Trainee
Research Award and TJC by Australian National Health & Research
Council Ideas Research Grant 1185813.
Declaration of Competing Interest
None.
Acknowledgements
Ross Carson is thanked for technical assistance and Uma Chandran
and Andrew Chang for assistance with mining GEO data sets.

10

J.D. Jaumotte et al.

Neurobiology of Disease 156 (2021) 105422

References

Lesage, F., et al., 2018. Preclinical evaluation of cell-based strategies to prevent or treat
bronchopulmonary dysplasia in animal models: a systematic review. J. Matern. Fetal
Neonatal Med. 31, 958–966.
Levine, S., 2002. Regulation of the hypothalamic-pituitary-adrenal axis in the neonatal
rat: the role of maternal behavior. Neurotox. Res. 4, 557–564.
Lian, J., et al., 2018. Carboxylesterases in lipid metabolism: from mouse to human.
Protein Cell. 9, 178–195.
Liddell, B.S., et al., 2017. Inhaled corticosteroid related adrenal suppression detected by
poor growth and reversed with ciclesonide. J. Asthma. 54, 99–104.
Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25, 402–408.
Lu, N.Z., Cidlowski, J.A., 2005. Translational regulatory mechanisms generate Nterminal glucocorticoid receptor isoforms with unique transcriptional target genes.
Mol. Cell 18, 331–342.
Lynch, J.T., et al., 2010. The role of glucocorticoid receptor phosphorylation in Mcl-1
and NOXA gene expression. Mol. Cancer 9, 38.
Maglione, M., et al., 2018. New drugs for pediatric asthma. Front. Pediatr. 6, 432.
Malaeb, S.N., Stonestreet, B.S., 2014. Steroids and injury to the developing brain: net
harm or net benefit? Clin. Perinatol. 41, 191–208.
Mars, U., et al., 2013. Tissue accumulation kinetics of ciclesonide-active metabolite and
budesonide in mice. Basic Clin. Pharmacol. Toxicol. 112, 401–411.
Matsuyama, S., et al., 2020. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA
replication by targeting the viral replication-transcription complex in cultured cells.
J. Virol. 95.
McGowan, P.O., Matthews, S.G., 2018. Prenatal stress, glucocorticoids, and
developmental programming of the stress response. Endocrinology. 159, 69–82.
Miller, J.A., et al., 2014. Transcriptional landscape of the prenatal human brain. Nature.
508, 199–206.
Mori, N., et al., 2021. Triple therapy with hydroxychloroquine, azithromycin, and
ciclesonide for COVID-19 pneumonia. J. Microbiol. Immunol. Infect. 54, 109–112.
Mutch, E., et al., 2007. The role of esterases in the metabolism of ciclesonide to
desisobutyryl-ciclesonide in human tissue. Biochem. Pharmacol. 73, 1657–1664.
Nave, R., McCracken, N., 2008. Metabolism of ciclesonide in the upper and lower
airways: review of available data. J. Asthma. Allergy. 1, 11–18.
Nave, R., et al., 2004. Pharmacokinetics of [14C]ciclesonide after oral and intravenous
administration to healthy subjects. Clin. Pharmacokinet. 43, 479–486.
Ng, P.C., et al., 2004. Transient adrenocortical insufficiency of prematurity and systemic
hypotension in very low birthweight infants. Arch. Dis. Child. Fetal Neonatal Ed. 89,
F119–F126.
Noguchi, K.K., 2014. Glucocorticoid induced cerebellar toxicity in the developing
neonate: implications for glucocorticoid therapy during bronchopulmonary
dysplasia. Cells. 3, 36–52.
Nonaka, T., et al., 2007. Ciclesonide uptake and metabolism in human alveolar type II
epithelial cells (A549). BMC Pharmacol. 7, 12.
Oakley, R.H., et al., 2018. Glucocorticoid receptor isoform-specific regulation of
development, circadian rhythm, and inflammation in mice. FASEB J. 32,
5258–5271.
Pedersen, S., et al., 2006. A comparative study of inhaled ciclesonide 160 microg/day
and fluticasone propionate 176 microg/day in children with asthma. Pediatr.
Pulmonol. 41, 954–961.
Pedersen, S., et al., 2010. Efficacy and safety of three ciclesonide doses vs placebo in
children with asthma: the RAINBOW study. Respir. Med. 104, 1618–1628.
Peffer, M.E., et al., 2014. Caveolin-1 regulates genomic action of the glucocorticoid
receptor in neural stem cells. Mol. Cell. Biol. 34, 2611–2623.
Peltoniemi, O., et al., 2005. Pretreatment cortisol values may predict responses to
hydrocortisone administration for the prevention of bronchopulmonary dysplasia in
high-risk infants. J. Pediatr. 146, 632–637.
Pew, B.K., et al., 2016. Structural and transcriptomic response to antenatal
corticosteroids in an Erk3-null mouse model of respiratory distress. Am. J. Obstet.
Gynecol. 215, 384 e1–384 e89.
Postma, D.S., et al., 2017. Asthma-related outcomes in patients initiating extrafine
ciclesonide or fine-particle inhaled corticosteroids. Allergy, Asthma Immunol. Res. 9,
116–125.
Rutkowska, M., et al., 2019. Severe bronchopulmonary dysplasia - incidence and
predictive factors in a prospective, multicenter study in very preterm infants with
respiratory distress syndrome. J. Matern. Fetal Neonatal Med. 32, 1958–1964.
Sato, H., et al., 2007. In vitro metabolism of ciclesonide in human nasal epithelial cells.
Biopharm. Drug Dispos. 28, 43–50.
Schittny, J.C., 2017. Development of the lung. Cell Tissue Res. 367, 427–444.
Sharma, V., McNeill, J.H., 2009. To scale or not to scale: the principles of dose
extrapolation. Br. J. Pharmacol. 157, 907–921.
Skoner, D.P., 2016. Inhaled corticosteroids: effects on growth and bone health. Ann.
Allergy Asthma Immunol. 117, 595–600.
Srinivasan, M., Lahiri, D.K., 2017. Glucocorticoid-induced leucine zipper in central
nervous system health and disease. Mol. Neurobiol. 54, 8063–8070.
Wang, D., et al., 2018. Human carboxylesterases: a comprehensive review. Acta Pharm.
Sin. B 8, 699–712.
Watterberg, K.L., et al., 2010. Policy statement–postnatal corticosteroids to prevent or
treat bronchopulmonary dysplasia. Pediatrics. 126, 800–808.
Weng, T., et al., 2006. Gene expression profiling identifies regulatory pathways involved
in the late stage of rat fetal lung development. Am. J. Phys. Lung Cell. Mol. Phys.
291, L1027–L1037.

Al-Safadi, S., et al., 2015. Glucocorticoids and stress-induced changes in the expression of
PERIOD1 in the rat forebrain. PLoS One 10, e0130085.
Bhatt, A.J., et al., 2013. Dexamethasone induces apoptosis of progenitor cells in the
subventricular zone and dentate gyrus of developing rat brain. J. Neurosci. Res. 91,
1191–1202.
Binder, E.B., 2009. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in
the pathogenesis and therapy of affective and anxiety disorders.
Psychoneuroendocrinology. 34 (Suppl. 1), S186–S195.
Bird, A.D., et al., 2014. Mesenchymal glucocorticoid receptor regulates the development
of multiple cell layers of the mouse lung. Am. J. Respir. Cell Mol. Biol. 50, 419–428.
Brand, P.L., et al., 2011. Ciclesonide in wheezy preschool children with a positive asthma
predictive index or atopy. Respir. Med. 105, 1588–1595.
Chen, W., et al., 2008. Glucocorticoid receptor phosphorylation differentially affects
target gene expression. Mol. Endocrinol. 22, 1754–1766.
Cheong, J.L., et al., 2014. Association between postnatal dexamethasone for treatment of
bronchopulmonary dysplasia and brain volumes at adolescence in infants born very
preterm. J. Pediatr. 164 (737–743), e1.
Daley-Yates, P.T., 2015. Inhaled corticosteroids: potency, dose equivalence and
therapeutic index. Br. J. Clin. Pharmacol. 80, 372–380.
Damsted, S.K., et al., 2011. Exogenous glucocorticoids and adverse cerebral effects in
children. Eur. J. Paediatr. Neurol. 15, 465–477.
Darbellay, F., Necsulea, A., 2020. Comparative transcriptomics analyses across species,
organs, and developmental stages reveal functionally constrained lncRNAs. Mol.
Biol. Evol. 37, 240–259.
Davidson, L.M., Berkelhamer, S.K., 2017. Bronchopulmonary dysplasia: chronic lung
disease of infancy and long-term pulmonary outcomes. J. Clin. Med. 6.
Davis, E.P., et al., 2013. Fetal glucocorticoid exposure is associated with preadolescent
brain development. Biol. Psychiatry 74, 647–655.
de Kloet, E.R., et al., 2014. Context modulates outcome of perinatal glucocorticoid action
in the brain. Front Endocrinol. (Lausanne) 5, 100.
Delahoy, M.J., et al., 2020. Characteristics and maternal and birth outcomes of
hospitalized pregnant women with laboratory-confirmed COVID-19 - COVID-NET,
13 states, march 1-august 22, 2020. MMWR Morb. Mortal. Wkly Rep. 69,
1347–1354.
Du, Y., et al., 2015. ‘LungGENS’: a web-based tool for mapping single-cell gene
expression in the developing lung. Thorax. 70, 1092–1094.
Du, Y., et al., 2017. Lung gene expression analysis (LGEA): an integrative web portal for
comprehensive gene expression data analysis in lung development. Thorax. 72,
481–484.
Ellington, S., et al., 2020. Characteristics of women of reproductive age with laboratoryconfirmed SARS-CoV-2 infection by pregnancy status - United States, January 22June 7, 2020. MMWR Morb. Mortal. Wkly Rep. 69, 769–775.
Feng, Y., et al., 2009. Dexamethasone induces neurodegeneration but also up-regulates
vascular endothelial growth factor A in neonatal rat brains. Neuroscience. 158,
823–832.
Galliher-Beckley, A.J., Cidlowski, J.A., 2009. Emerging roles of glucocorticoid receptor
phosphorylation in modulating glucocorticoid hormone action in health and disease.
IUBMB Life 61, 979–986.
Guo, M., et al., 2019. Single cell RNA analysis identifies cellular heterogeneity and
adaptive responses of the lung at birth. Nat. Commun. 10, 37.
Heine, V.M., Rowitch, D.H., 2009. Hedgehog signaling has a protective effect in
glucocorticoid-induced mouse neonatal brain injury through an 11betaHSD2dependent mechanism. J. Clin. Invest. 119, 267–277.
Holmes, R.S., et al., 2010. Recommended nomenclature for five mammalian
carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm.
Genome 21, 427–441.
Ilg, L., et al., 2019. Persistent effects of antenatal synthetic glucocorticoids on endocrine
stress reactivity from childhood to adolescence. J. Clin. Endocrinol. Metab. 104,
827–834.
Jeon, S., et al., 2020. Identification of antiviral drug candidates against SARS-CoV-2 from
FDA-approved drugs. Antimicrob. Agents Chemother. 64.
Jones, R.D., et al., 2013. Carboxylesterases are uniquely expressed among tissues and
regulated by nuclear hormone receptors in the mouse. Drug Metab. Dispos. 41,
40–49.
Kalikkot Thekkeveedu, R., et al., 2017. Bronchopulmonary dysplasia: a review of
pathogenesis and pathophysiology. Respir. Med. 132, 170–177.
Keil, J.M., et al., 2018. Brain transcriptome databases: a User’s guide. J. Neurosci. 38,
2399–2412.
Kim, J.W., et al., 2013. Administration of dexamethasone to neonatal rats induces
hypomyelination and changes in the morphology of oligodendrocyte precursors.
Comp. Med. 63, 48–54.
Kraft, K.E., et al., 2019. Functional outcome at school age of preterm-born children
treated with low-dose dexamethasone in infancy. Early Hum. Dev. 129, 16–22.
Lee, H.J., et al., 2012. Effects of postnatal dexamethasone or hydrocortisone in a rat
model of antenatal lipopolysaccharide and neonatal hyperoxia exposure. J. Korean
Med. Sci. 27, 395–401.
LeFlore, J.L., Engle, W.D., 2011. Growth and neurodevelopment in extremely low-birthweight neonates exposed to postnatal steroid therapy. Am. J. Perinatol. 28, 635–642.

11

